Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Optison Clear all
Completed Phase 4 Interventional Results available

Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

NCT03740997
View directory record Official record
Conditions
Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality
Interventions
Optison
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
9 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children

NCT02204917
View directory record Official record
Conditions
Vesico-Ureteral Reflux
Interventions
OPTISON
Drug
Lead sponsor
Kassa Darge
Other
Eligibility
Up to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.

NCT00730964
View directory record Official record
Conditions
Echocardiography
Interventions
Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
1,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Not applicable Interventional

Pre-operative Evaluation of Kidney & Pancreas Transplant Patients

NCT00580437
View directory record Official record
Conditions
Kidney Transplantation, Pancreas Transplantation
Interventions
Dobutamine Stress Echocardiogram
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 3, 2026, 9:46 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Contrast-Enhanced Ultrasound in Human Crohn's Disease

NCT02061163
View directory record Official record
Conditions
Crohn's Disease
Interventions
Contrast Enhanced Ultrasound, Optison
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
10 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema

NCT05613946
View directory record Official record
Conditions
Lymphedema Arm
Interventions
Lumason, Optison, Definity
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 3, 2026, 9:46 AM EDT
Withdrawn No phase listed Observational

The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals

NCT02560116
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 2 Interventional Results available

Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

NCT05328167
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 2 Interventional Results available

Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

NCT02440334
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Optison
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 3, 2026, 9:46 AM EDT
Not yet recruiting No phase listed Observational

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 3, 2026, 9:46 AM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease

NCT01394926
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Optison
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

NCT00878878
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Elliott, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

NCT00186953
View directory record Official record
Conditions
Abdominal Neoplasms, Pelvic Neoplasms
Interventions
Optison
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 3, 2026, 9:46 AM EDT
Withdrawn Early Phase 1 Interventional

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery

NCT02671552
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?

NCT02625428
View directory record Official record
Conditions
Transplantation, Kidney
Interventions
Optison, Ultrasound (US), Contrast-enhanced ultrasound (CEUS)
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 3, 2026, 9:46 AM EDT
Terminated Not applicable Interventional

Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair

NCT01230684
View directory record Official record
Conditions
Endograft Implantation to Repair Abdominal Aortic Aneurysm
Interventions
Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 3, 2026, 9:46 AM EDT
Not listed Not applicable Interventional

Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery & Risk Area in Patients w/ NSTEMI.

NCT02014701
View directory record Official record
Conditions
STEMI
Interventions
Echocardiogram
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
31 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma

NCT01763840
View directory record Official record
Conditions
Abdominal Trauma
Interventions
Contrast enhanced Ultrasound
Drug
Lead sponsor
David Mooney
Other
Eligibility
2 Years to 35 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage

NCT01721447
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Optison echocardiography contrast agent
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 3 Interventional Results available

Regadenoson Real Time Perfusion Imaging Trial-Optison

NCT01489176
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Perfusion Abnormalities
Interventions
Regadenoson; Optison
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

NCT02321527
View directory record Official record
Conditions
Breast Cancer
Interventions
Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement, Phone Call
Drug · Device · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 3, 2026, 9:46 AM EDT
Completed Phase 2 Interventional Results available

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

NCT03199274
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 3, 2026, 9:46 AM EDT
Terminated No phase listed Observational

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

NCT02300870
View directory record Official record
Conditions
Heart Transplantation
Interventions
Optison
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 3, 2026, 9:46 AM EDT
Completed No phase listed Observational

Contrast Enhanced PA Pressure Measurements

NCT06240871
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Pulmonary artery pressure measurements
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 3, 2026, 9:46 AM EDT